<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368654</url>
  </required_header>
  <id_info>
    <org_study_id>200513613</org_study_id>
    <nct_id>NCT00368654</nct_id>
  </id_info>
  <brief_title>Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy</brief_title>
  <official_title>An Open-Label Study to Evaluate Whether a Short-Term Course of Methotrexate in Psoriasis Patients Treated With Efalizumab is Safe and Increases Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether a short-term course of methotrexate in patients treated with efalizumab
      (Raptiva) increases efficacy. The secondary objectives of this study are 1) to evaluate the
      efficacy of Raptiva in maintaining the clinical improvement induced by short-term treatment
      with combination therapy of Raptiva and methotrexate 2) to evaluate the safety of short-term
      combination therapy of Raptiva and methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate whether a short-term course of
      methotrexate in patients treated with efalizumab (Raptiva) increases efficacy. The secondary
      objectives of this study are 1) to evaluate the efficacy of Raptiva in maintaining the
      clinical improvement induced by short-term treatment with combination therapy of Raptiva and
      methotrexate 2) to evaluate the safety of short-term combination therapy of Raptiva and
      methotrexate.

      The design of this study is to gain better control of the disease process while reducing
      potential toxicities by beginning treatment with Raptiva and adding methotrexate to those
      patients who do not improve significantly
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI -- psoriasis area and severity index</measure>
    <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
    <description>(PASI) - given by numerical score, the index shows the severity of psoriasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events (AE)</measure>
    <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
    <description>measured by whether or not AE was serious</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy with Raptiva alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with both Raptiva and Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue Raptiva, discontinue methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue combination therapy with both Raptiva and Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Initial dose 5 mg, then 15 mg per week</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
    <description>Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Efalizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe plaque-type psoriasis

          -  A candidate for systemic therapy or phototherapy

          -  Not using prescription systemic therapies for psoriasis prior to starting the study

          -  Not using efalizumab within 3 months prior to starting the study

        We are seeking adults who:

          -  Have moderate to severe plaque-type psoriasis

          -  Are generally healthy

          -  Are not hypersensitive to RaptivaÂ® (efalizumab) or any of its components.

          -  Are not pregnant or lactating women

        You will:

          -  Be interviewed and examined

          -  Have blood drawn

          -  Be injecting the study medication

        Exclusion Criteria:

          -  Hypersensitivity to Raptiva or any of its components

          -  Pregnant or lactating women

          -  History of liver disease or abnormal liver enzymes

          -  History of chronic infection or malignancy

          -  History of significant hematologic abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chai Sue Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center Department of Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ucdmc.ucdavis.edu/dermatology/research/clinical</url>
    <description>University of California-Davis Department of Dermatology Clinical Research</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2006</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 11, 2017</submitted>
    <returned>January 8, 2018</returned>
    <submitted>January 26, 2018</submitted>
    <returned>February 22, 2018</returned>
    <submitted>February 27, 2018</submitted>
    <returned>March 27, 2018</returned>
    <submitted>May 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

